Garuda - Garba Rujukan Digital

Article Per Year (5 Year)

All

The Indonesian Journal of Gastroenterology, Hepatology and Digestive Endoscopy

jghe
Website

Published by The Indonesian Society for Digestive Endoscopy

ISSN : 14114801 EISSN : 23028181 DOI : -

Core Subject : Health,

Medicine & Pharmacology

The Indonesian Journal of Gastroenterology, Hepatology and Digestive Endoscopy is an academic journal which has been published since 2000 and owned by 3 Societies: The Indonesian Society of Gastroenterology; Indonesian Association for the Study of the Liver; The Indonesian Society for Digestive Endoscopy. The aim of our journal is to advance knowledge in Gastroenterology, Hepatology, and Digestive Endoscopy fields. We welcome authors for original articles, review articles, and case reports in the fields of Gastroenterology, Hepatology, and Digestive Endoscopy.

Arjuna Subject : Kedokteran - Ilmu Pencernaan

Articles 771 Documents

35 36 37 38 39

Sarcopenia is Associated with Poor Performance Status in Indonesian Patients with Hepatocellular Carcinoma Koncoro, Hendra; Hasan, Irsan; Lesmana, C Rinaldi; Aditama, Humala Prika; Salamah, Thariqah; Rizka, Aulia; Wahyudi, Edy Rizal; Shatri, Hamzah; Teng, Wei
The Indonesian Journal of Gastroenterology, Hepatology, and Digestive Endoscopy Vol 23, No 1 (2022): VOLUME 23, NUMBER 1, April 2022
Publisher : The Indonesian Society for Digestive Endoscopy

Background: Sarcopenia has a notable impact on the prognosis of hepatocellular carcinoma (HCC). The prevalence of sarcopenia in patients with HCC is relatively high, with studies reporting rates between 39% and 41.7%. A substantial proportion of individuals diagnosed with HCC also exhibit muscle wasting and reduced muscle function. This study aims to determine the prevalence of sarcopenia in Indonesian patients with HCC (based on the Japanese Socuety of Hepatology (JSH) JSH criteria) and to examine its correlation with poor performance status.Methods: We performed a cross-sectional study of 85 HCC patients between January and October 2021). The skeletal muscle index at L3 (L3 SMI) was measured on CT scans (applying JSH cut-offs for sarcopenia). Clinical data, including Eastern Cooperative Oncology Group (ECOG) performance status, were collected. Bivariate analyses and logistic regression were performed to identify factors associated with sarcopenia.Results: A total of 85 HCC patients (median age: 52 years) were included in the analysis. Sarcopenia was observed in 49.4% of the cohort. Bivariate analysis revealed a statistically significant association between sarcopenia and an ECOG performance status of 2+ (p = 0.003), as well as a MELD-Na score of ≥15 (p = 0.023). In multivariate analysis, poor ECOG-PS remained independently associated with sarcopenia (adjusted OR 4.17; 95% CI 1.50–11.56, p = 0.006).Conclusion: Sarcopenia is highly prevalent among Indonesian HCC patients, and it is strongly associated with poor ECOG performance status.

Soy Infant and Extensively Hydrolyzed Formula as Therapeutic Formula for Cow’s Milk Protein Allergy Aldo Reynaldo; Badriul Hegar
The Indonesian Journal of Gastroenterology, Hepatology, and Digestive Endoscopy Vol 15, No 2 (2014): VOLUME 15, NUMBER 2, August 2014
Publisher : The Indonesian Society for Digestive Endoscopy

Cow’s milk protein allergy (CMPA) is a food allergy mostly suffered by children aged 3 years that can be mediated by IgE or non-IgE or both. The prevalence of CMPA in children is heterogeneous between populations. Meta-analysis study showed that the prevalence was 2-3% in infants and 1% in children aged 6 years. Although the prevalence is quite small but proper management is very important because it affects the quality of life of children and to avoid the risk of anaphylactic reaction that threatens life. Therapy for CMPA is to avoid cow's milk protein and its derivatives; it is also recommended for breast-feeding mothers to do the same. Therapeutic milk formulas that can be given is extensively hydrolyzed formula (eHF) or soy infant formula (SIF). The selection of formula became adebate, especially about the safety, effectiveness and cost. Keywords: cow milk protein allergy, soy infant formula, extensively hydrolyzed formula

Prevalence and Distribution of Anemia Risk Factor in Patient with Chronic Hepatitis C who Has Combination therapy of Interferon Alpha and Ribavirin Femmy Nurul Akbar; Zuljasri Albar; Abdul Muthalib; Laurentius Lesmana; Nurul Akbar
The Indonesian Journal of Gastroenterology, Hepatology, and Digestive Endoscopy VOLUME 7, ISSUE 1, April 2006
Publisher : The Indonesian Society for Digestive Endoscopy

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.24871/7120066-10

Background: Interferon alfa and ribavirin combination therapy is one of effective standard therapy for chronic hepatitis C (CHC.) However, anemia is a common side effect of this therapy that patients have to reduce or discontinue ribavirin therapy. But ribavirin dose reduction or discontinuation can reduce the effectivity of the therapy. Hence, it is important to know the prevalence of anemia and to determine the factors associated with anemia. Objective: To know the prevalence of anemia and some risk factors associated with anemia caused by the combination therapy in chronic hepatitis C. Method: Sixty one of CHC patients who received combination therapy were included in this study. The study used cross sectional design and data were obtained by measured complete blood count on 8th week of therapy. Result: Subjects 47 (77%) were males, 14 (23%) were females with mean age 38.9 years. Subjects had genotype 1 and 4 were 23 (71.9%) and 44 (72.1%) subjects received 1,000 mg ribavirin. Prevalence of anemia was found to be 52.5%. On multivariate analysis, only pretreatment hemoglobin concentration 14 g/dl was found to be the risk factor of anemia. Conclusion: Prevalence of anemia was 52.5%. Pretreatment hemoglobin concentration 14 g/dl was only found to be the risk factors of anemia. Although age 50 years or female were not found to be the risk factor of anemia but patient with these risk factors should be carefully monitored. Intervention to prevent anemia should be considered to these patients. Eight subjects from 32 anemia patients had ribavirin dose reduction, and no patient had discontinuation treatment on 8th week of therapy. Keywords: chronic hepatitis C, IFN-alfa- RIB combination therapy, risk factors of anemia

The Role of M2 Pyruvate Kinase in the Screening of Bowel Inflammation Ruswhandi -; Marcellus Simadibrata; Irsan Hasan
The Indonesian Journal of Gastroenterology, Hepatology, and Digestive Endoscopy Vol 16, No 1 (2015): VOLUME 16, NUMBER 1, April 2015
Publisher : The Indonesian Society for Digestive Endoscopy

Background: This is a study to determine if M2 Pyruvate Kinase (M2-PK) can be used to screen the presence of bowel inflammation.Method: The study design being used is diagnostic test. In this study, we recruited 76 participants and performed colonoscopy examination as a gold standard and faecal M2-PK as the examined procedure.Results: From the result of this study, we identified the important role of M2-PK to screen the presence of bowel inflammation with the cut-off point of 1.05 U/mL compared to colonoscopy as gold standard with the sensitivity of 86.2%, specificity 81.8%, positive predictive value 96.6%, and negative predictive value 50%.Conclusion: From the result of this study, we suggested M2-PK examination to screen bowel inflammation in patients with lower gastrointestinal tract problems.

Achalasia Carcinoma Sequence Dadang Makmun
The Indonesian Journal of Gastroenterology, Hepatology, and Digestive Endoscopy VOLUME 2, NUMBER 3, December 2001
Publisher : The Indonesian Society for Digestive Endoscopy

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.24871/23200128-30

We report a case of carcinoma of the esophagus in a 58 years old woman with achalasia, who has been diagnosed since 30 years ago, which initiated by surgical treatment (myotomy) and the symptoms recurred since 3 years ago. According to the progress of the disease, malignancy was strongly suspected due to prolonged stasis and mucosal irritation caused by achalasia (achalasia carcinoma sequence). Because of these contributing factors for the development of serious complications such as malignancy, the diagnosis of achalasia must be systematically diagnosed and treated agressively. Surveillance endoscopy in patients with achalasia should be performed every 1-2 years. Key words: achalasia carcinoma sequence, surveillance endoscopy

One-year Survival Rate of Pancreatic Cancer and the Mortality Affecting Factors Alexander Michael Joseph Saudale; Marcellus Simadibrata; Rino Alvani Gani; Cleopas Martin Rumende
The Indonesian Journal of Gastroenterology, Hepatology, and Digestive Endoscopy Vol 21, No 2 (2020): VOLUME 21, NUMBER 2, August 2020
Publisher : The Indonesian Society for Digestive Endoscopy

Background: Pancreatic cancer is the fourth leading cause of death associated with malignancy in the United States, and is thought to be the second leading cause of death in 2030 in the United Kingdom. In Asia, pancreatic cancer is the most fatal cancer with the lowest survival of all malignancies, 25-30% survival five years after surgery. Indonesia has no data on the survival of pancreatic cancer and the factors that affect it. The aim of this study is knowing the 1-year survival of pancreatic cancer and its influencing factors in Cipto Mangunkusumo Hospital, Jakarta.Method: A retrospective cohort study was performed using data from the medical records of pancreatic cancer patients dr. Cipto Mangunkusumo Hospital between January 2012 - December 2016. Factors age, sex, metastasis, stage, comorbid and treatment were analyzed bivariate and multivariate using Cox Proportional Hazards Regression to obtain Hazard Ratio (HR) for each prognostic factor. The cumulative survival of 1 year after diagnosis is expressed by the Kaplan-Meier curve.Results: Of 83 subjects the proportion of males was 62.7%, age ≥ 50 years 68.7%, with age range 33-79 years, and 55 years on average. In bivariate analysis, there was a statistically significant relationship of survival with comorbid variables (HR = 2,116, 95% 953 1,335-3,513, p 0,002), metastasis (HR = 3,802, 95% CI: 1,995-7,249, p 0.001), palliative treatment (HR = 2,108 , 95% CI: 1,077-4,125, p = 0,029) and group without treatment (HR = 2,924, 95% CI: 1,496-5,716, p = 0,002). Multivariate analysis showed that metastasis provided the greatest risk of death with HR = 4.306 (95% CI: 2.125-8.724, p 0.001). Palliative group HR was 2.510 (95% CI: 1,245-5,061 p = 0.010) while the group without treatment gave HR 2,535 (95% CI: 1,277-5,032 p = 0,008). The 1-year survival rate is 14%, with a median survival of 6 months.Conclusion: The overall survival of one year of pancreatic cancer patients was 14%, with a median survival of 6 months. The presence of metastasis and not the curative therapy of Whipple surgery in patients with pancreatic cancer in dr. Cipto Mangunkusumo Hospital is the main factor that negatively affect the survival of 1 year

The Future of Acid Inhibition Guido NJ Tytgat
The Indonesian Journal of Gastroenterology, Hepatology, and Digestive Endoscopy VOLUME 12, NUMBER 3, December 2011
Publisher : The Indonesian Society for Digestive Endoscopy

There are many unmet needs with current gastric acid suppression with proton pump inhibitors (PPIs). Recommended prescription of one standard morning dose for all patients and for all medical conditions must be scientifically inappropriate and far from individualized personal medicine. For several diseases, especially gastroesophageal reflux disease and Barrett esophagus, more intense, more prolonged diurnal acid suppression is indicated. Especially inhibition of nocturnal acid secretion with our current delayed-release PPIs turns out to be difficult. This overview summarizes the actual attempts to improve the control of acid secretion, which is necessary to adapt the degree of acid inhibition to the individual patient needs. To be discussed are: immediately release PPIs, extended PPI formulations, PPIs with a much longer half-life, potassium competitive acid blockers, gastrin antagonists, etc. Future studies have to proof that those novel drug approaches indeed contribute to reduce the unmet needs. Keywords: acid secretion, PPI, nocturnal acid secretion

Eosinophilic Esophagitis T Yuli Pramana; Marcellus Simadibrata
The Indonesian Journal of Gastroenterology, Hepatology, and Digestive Endoscopy VOLUME 8 ISSUE 2 August 2007
Publisher : The Indonesian Society for Digestive Endoscopy

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.24871/82200748-52

The frequency of eosinophilic esophagitis (EE) cases is increasing along with increased understanding among doctors about EE. In the beginning, EE is mostly found in children population. It was first reported in adults by Landres on 1978. The prominent EE symptoms in adults are dysphagia and solid food impaction. Endoscopic examination reveals mucous ring of esophagus, white plaque on the mucosa. The diagnosis is supported by positive result of eosinophils, which forms infiltration on the mucosaof 20 eosinophils/ high power field in the distal or middle esophagus. Treatment by using diet and corticosteroid, either topical or systemic, shows adequate results. Immunomodulator treatment is promising, but it needs further investigation with larger sample. No consensus have been reached for EE, therefore it may affect the diagnosis, treatment and epidemiology data. Keywords: esophagus, eosinophil, dysphagia, ring of esophagus

Achalasia: A Review of Etiology, Pathophysiology, and Treatment Nor Hedayanti; Supriono Supriono
The Indonesian Journal of Gastroenterology, Hepatology, and Digestive Endoscopy Vol 17, No 1 (2016): VOLUME 17, NUMBER 1, April 2016
Publisher : The Indonesian Society for Digestive Endoscopy

Achalasia was a condition marked by peristaltic movement absent in lower esophageal sphincter and segment that hypertonic result in imperfect relaxation during food ingestion. Achalasia incidence did not differ between men and women, account for 1 in 100.000 people every year with prevalence of 10 in 100.000 people, unrelated specifically with ethnic, and has its highest incidence on 30-60 age group.Based on its etiology, it was divided into primary and secondary Achalasia, while based on its motility, it was into hypermotil, hypomotil, and amotil Achalasia. Until present, several therapeutic modalities were available to treat Achalasia, among them was pharmacology therapy, botulinum toxin injection via endoscopy, pneumatic dilatation, Heller myotomy surgery, and Per Oral Endoscopy Myotomy (POEM).

Incidence of Colorectal Cancer in Saiful Anwar Hospital, Malang January 2010- April 2015 Lia Sasmithae; Syifa Mustika
The Indonesian Journal of Gastroenterology, Hepatology, and Digestive Endoscopy Vol 18, No 3 (2017): VOLUME 18, NUMBER 3, DECEMBER 2017
Publisher : The Indonesian Society for Digestive Endoscopy

Background: Colorectal carcinoma is the third most common malignancy worldwide and the second most frequently found cause of mortality in the United States. In Indonesia, the number of colorectal cancer patients ranks 10th (2.75%) after other cancers (cervical, breast, lymph nodes, skin, nasopharyngeal, ovarium, soft tissue, and thyroid). The main key to success in managing this carcinoma is by detecting the cancer in early stage to enable curative treatment to be performed. But, unfortunately most patients in Indonesia seek for treatment in the advanced stage, causing low survival rate. Colorectal carcinoma requires multimodalities management and there is no uniformity of management approach in the national level. This study was aimed to identify the incidence, epidemiology, and risk factors which influence the occurrence of colon and rectal cancer in Saiful Anwar Hospital (SAH), Malang based on colonoscopy examination from January 2010-April 2015.Method: Descriptive study, with total sampling method. Samples were colon and rectal cancer patients in SAH, Malang who underwent colonoscopy within January 2010 – April 2015.Results: We found 472 eligible samples, which comprised of 50 individuals (11%) with the age of less than 36 years old, 326 individuals (69%) in middle aged group with the age of 36-65 years old, 96 individuals (20%) in older aged group with the age of more than 65 years old. Patients were predominantly male with 248 individuals (53%), while female patients were 224 individuals (47%). The most common location of the tumour was in the rectum, which was found in 380 individuals (74.15%). The most common clinical symptoms was bloody stool with mucus. From patients in this study, 87 individuals (18.43%) had history of smoking, 11 individuals (2.3%) had family history of cancer, and 58 individuals (12.28%) consumed traditional herbal drinks (jamu). Patients’ characteristics of colon cancer based on anatomical pathology results showed that the most common was moderately differentiated adenocarcinoma in 33 patients (61.11%), followed by well-differentiated adenocarcinoma in 14 patients (25.93%), and the least common was those with anatomical pathology results revealing unspecific adenocarcinoma in 7 patients (12.96%). Characteristics of patients with rectal cancer based on anatomical pathology results showed that the most commonly found was moderately differentiated adenocarcinoma in 72 patients (54.15%), well-differentiated adenocarcinoma in 34 patients (25.56%), unspecific adenocarcinoma in 24 patients (18.04%) and the least common was those with anatomical pathology results of mucinous adenocarcinoma found in 3 patients (2.25%).Conclusion: The conclusion of this study was colon and rectal cancer were frequently found in middle aged group. The most common location was rectum. Mainly found in male compared to female.

Page 37 of 78 | Total Record : 771

35 36 37 38 39

Filter by Year

2000 2025

Filter By Issues

All Issue Vol 26, No 2 (2025): VOLUME 26, NUMBER 2, AGUSTUS, 2025 Vol 26, No 1 (2025): VOLUME 26, NUMBER 1, April, 2025 Vol 25, No 3 (2024): VOLUME 25, NUMBER 3, December, 2024 Vol 25, No 2 (2024): VOLUME 25, NUMBER 2, August, 2024 Vol 25, No 1 (2024): VOLUME 25, NUMBER 1, April, 2024 Vol 24, No 3 (2023): VOLUME 24, NUMBER 3, December, 2023 Vol 24, No 2 (2023): VOLUME 24, NUMBER 2, August, 2023 Vol 24, No 1 (2023): VOLUME 24, NUMBER 1, April, 2023 Vol 23, No 3 (2022): VOLUME 23, NUMBER 3, December 2022 Vol 23, No 2 (2022): VOLUME 23, NUMBER 2, August 2022 Vol 23, No 1 (2022): VOLUME 23, NUMBER 1, April 2022 Vol 22, No 3 (2021): VOLUME 22, NUMBER 3, December 2021 Vol 22, No 2 (2021): VOLUME 22, NUMBER 2, August 2021 Vol 22, No 1 (2021): VOLUME 22, NUMBER 1, April 2021 Vol 21, No 3 (2020): VOLUME 21, NUMBER 3, December 2020 Vol 21, No 2 (2020): VOLUME 21, NUMBER 2, August 2020 Vol 21, No 1 (2020): VOLUME 21, NUMBER 1, April 2020 Vol 20, No 3 (2019): VOLUME 20, NUMBER 3, December 2019 Vol 20, No 2 (2019): VOLUME 20, NUMBER 2, August 2019 Vol 20, No 1 (2019): VOLUME 20, NUMBER 1, April 2019 Vol 19, No 3 (2018): VOLUME 19, NUMBER 3, December 2018 Vol 19, No 2 (2018): VOLUME 19, NUMBER 2, August 2018 Vol 19, No 1 (2018): VOLUME 19, NUMBER 1, April 2018 Vol 18, No 3 (2017): VOLUME 18, NUMBER 3, DECEMBER 2017 Vol 18, No 2 (2017): VOLUME 18, NUMBER 2, AUGUST 2017 Vol 18, No 1 (2017): VOLUME 18, NUMBER 1, April 2017 Vol 17, No 3 (2016): VOLUME 17, NUMBER 3, December 2016 Vol 17, No 2 (2016): VOLUME 17, NUMBER 2, August 2016 Vol 17, No 1 (2016): VOLUME 17, NUMBER 1, April 2016 Vol 16, No 3 (2015): VOLUME 16, NUMBER 3, December 2015 Vol 16, No 2 (2015): VOLUME 16, NUMBER 2, August 2015 Vol 16, No 1 (2015): VOLUME 16, NUMBER 1, April 2015 Vol 15, No 3 (2014): VOLUME 15, NUMBER 3, December 2014 Vol 15, No 2 (2014): VOLUME 15, NUMBER 2, August 2014 Vol 15, No 1 (2014): VOLUME 15, NUMBER 1, April 2014 VOLUME 14, NUMBER 3, December 2013 VOLUME 14, NUMBER 2, August 2013 VOLUME 14, NUMBER 1, April 2013 VOLUME 13, NUMBER 3, Desember 2012 VOLUME 13, NUMBER 2, August 2012 VOLUME 13, NUMBER 1, April 2012 VOLUME 12, NUMBER 3, December 2011 VOLUME 12, NUMBER 2, August 2011 VOLUME 12, NUMBER 1, April 2011 VOLUME 11, NUMBER 3, December 2010 VOLUME 11, NUMBER 2, August 2010 VOLUME 11, NUMBER 1, April 2010 VOLUME 10, NUMBER 3, December 2009 VOLUME 10, ISSUE 2, August 2009 VOLUME 10, ISSUE 1, April 2009 VOLUME 9, ISSUE 3, December 2008 VOLUME 9, ISSUE 2, August 2008 VOLUME 9, ISSUE 1, April 2008 VOLUME 8, ISSUE 3, December 2007 VOLUME 8 ISSUE 2 August 2007 VOLUME 8, ISSUE 1, April 2007 VOLUME 7, ISSUE 3, December 2006 VOLUME 7, ISSUE 2, August 2006 VOLUME 7, ISSUE 1, April 2006 VOLUME 6, ISSUE 3, December 2005 VOLUME 6, ISSUE 2, August 2005 VOLUME 6, ISSUE 1, April 2005 VOLUME 5, ISSUE 3, December 2004 VOLUME 5, ISSUE 2, August 2004 VOLUME 5, ISSUE 1, April 2004 VOLUME 4, ISSUE 3, December 2003 VOLUME 4, ISSUE 2, August 2003 VOLUME 4, NUMBER 1, April 2003 VOLUME 3, NUMBER 3, December 2002 VOLUME 3, NUMBER 2, August 2002 VOLUME 3, NUMBER 1, April 2002 VOLUME 2, NUMBER 3, December 2001 VOLUME 2, NUMBER 2, August 2001 VOLUME 2, NUMBER 1, April 2001 VOLUME 1, NUMBER 1, December 2000 More Issue

Home Page

OAI Link

Editorial Team

Contact

Reviewer

Google Scholar

Contact Name
Murdani Abdullah

Contact Email
ina.jghe@gmail.com

Phone
+6285891498517

Journal Mail Official
ina.jghe@gmail.com

Editorial Address
Divisi Gastroenterologi, Departemen Ilmu Penyakit Dalam, FKUI/RSUPN Dr. Cipto Mangunkusumo, Jl. Diponegoro No. 71 Jakarta 10430 Indonesia

Location
Kota adm. jakarta pusat,

Dki jakarta

INDONESIA

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Home Page

OAI Link

Editorial Team

Contact

Reviewer

Google Scholar

Contact Name Murdani Abdullah

Contact Email ina.jghe@gmail.com

Phone +6285891498517

Journal Mail Official ina.jghe@gmail.com

Editorial Address Divisi Gastroenterologi, Departemen Ilmu Penyakit Dalam, FKUI/RSUPN Dr. Cipto Mangunkusumo, Jl. Diponegoro No. 71 Jakarta 10430 Indonesia

Location Kota adm. jakarta pusat, Dki jakarta INDONESIA

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Contact Name
Murdani Abdullah

Contact Email
ina.jghe@gmail.com

Phone
+6285891498517

Journal Mail Official
ina.jghe@gmail.com

Editorial Address
Divisi Gastroenterologi, Departemen Ilmu Penyakit Dalam, FKUI/RSUPN Dr. Cipto Mangunkusumo, Jl. Diponegoro No. 71 Jakarta 10430 Indonesia

Location
Kota adm. jakarta pusat,

Dki jakarta

INDONESIA